How much funding has Arpeggio Bio raised?

Arpeggio Bio has raised $40.2M in total funding, most recently a Series B round.

Who are Arpeggio Bio's investors?

Arpeggio Bio's investors include Khosla Ventures, venBIO Partners, Builders VC, FundersClub, Fifty Years, Ms2 Capital.

When was Arpeggio Bio founded?

Arpeggio Bio was founded in 2018.

Where is Arpeggio Bio headquartered?

Arpeggio Bio is headquartered in Boulder, Colorado, United States.

What industry is Arpeggio Bio in?

Arpeggio Bio operates in Biotech, Drug Discovery, Genomics, Healthcare.

How many employees does Arpeggio Bio have?

Arpeggio Bio has 11-50 employees.

Arpeggio Bio

Arpeggio Bio develops drugs targeting transcription factors using AI…

Boulder, United States · Founded 2018 · $40.2M raised

YC S19

Headquarters: Boulder, Colorado
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: arpeggiobio.com
Total Funding: $40.2M
Last Round: $20.0M Series BNov 2025
Rounds: 3

About

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

Summary

Arpeggio Bio is a Biotech company based in Boulder, United States, founded in 2018. It has raised $40.2M in total across 3 rounds, most recently a $20.0M Series B round in Nov 2025. Investors include Khosla Ventures, venBIO Partners and Builders VC.

LinkedIn X (Twitter)